NVO - Veru to conduct Phase2b study with enobosarm GLP-1 weight-loss drugs
2023-10-04 10:05:55 ET
More on Veru
- Veru Inc. (VERU) Q2 2023 Earnings Call Transcript
- Stay Away From Veru Until 2024
- Seeking Alpha’s Quant Rating on Veru
- Historical earnings data for Veru
- Financial information for Veru
For further details see:
Veru to conduct Phase2b study with enobosarm, GLP-1 weight-loss drugs